Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | HTR2A | P28223 | 7/20 | 0.53 |
| ▸ | DRD3 | P35462 | 7/20 | 0.53 |
| ▸ | PHGDH | O43175 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15971536 | 0.86 | HTR2C (0.73) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL15971496 | 0.85 | HTR2C (0.71) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL14983624 | 0.84 | HTR2C (0.62) | HTR2CHRH4DRD2HTR2ADRD3 | |
| SCHEMBL15971543 | 0.84 | HTR2C (0.62) | HTR2CHRH4DRD2HTR2ADRD3 | |
| SCHEMBL28038474 | 0.83 | HTR2C (0.69) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL4935508 | 0.83 | HTR2C (0.69) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL1601087 | 0.83 | HTR2C (0.69) | HTR2CDRD2HTR2ADRD3PHGDH | |
| SCHEMBL15971545 | 0.83 | HTR2C (0.64) | HTR2CHRH4DRD2HTR2ADRD3 | |
| SCHEMBL11835040 | 0.82 | DRD2 (0.61) | HTR2CDRD2HTR2ADRD3 | |
| SCHEMBL1026755 | 0.82 | HTR2C (1.00) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-2958920-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | HTR2C 14/4885HRH4 38/4885DRD2 172/4885 |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | HTR2C 541/4885HRH4 539/4885DRD2 743/4885 |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | CCNI, F12, MKI67 | HTR2C 2049/4885HRH4 129/4885DRD2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.